[Clinical studies on the fibrinolytic action of pentosan polysulfate].
The influence on fibrinolysis of the heparin-like substance Polyanion SP 54 is described. In vitro tests showed an increase of fibrinolysis by activation of the endogenous pathway via factor XII and prekallikrein. In vivo an increase of the availability of tissue plasminogen activator was assumed in addition. When different ways of administration of Polyanion SP 54 were tested an enhancement of fibrinolysis was also found after oral application of the substance. In a long term test the stimulation of fibrinolysis after oral therapy did not diminish within 12 months. A trial on patients with cerebral ischemic attacks and diminished fibrinolysis is not yet concluded but permits the assumption of a considerable diminution of ischemic attacks during therapeutic use of Polyanion SP 54.
D000284:Administration, Oral; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D005174:Factor XII / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects*; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D002546:Ischemic Attack, Transient / Q000097:blood / Q000188:drug therapy*; D010426:Pentosan Sulfuric Polyester / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011134:Polysaccharides / Q000627:therapeutic use*; D012016:Reference Values; D012712:Serum Globulins / Q000032:analysis
D011134:Polysaccharides; D012712:Serum Globulins; D010426:Pentosan Sulfuric Polyester; D005174:Factor XII
Klinische Untersuchungen zur fibrinolytischen Wirkung von Pentosanpolysulfat.